US Justice Dept cracks down on healthcare fraud schemes linked to $2.75bn loss
The US Justice Department has charged 193 people in a major enforcement action, accusing them of participating in healthcare fraud …
The US Justice Department has charged 193 people in a major enforcement action, accusing them of participating in healthcare fraud …
The US Supreme Court has obstructed a settlement that would have shielded the OxyContin producer, Purdue Pharma from future litigation …
On 17 June, Amylyx acquired the rights to Eiger Biopharmaceutical’s experimental glucagon-like peptide-1 (GLP-1) receptor antagonist, avexitide, for $35.1m. Avexitide …
Coherus Biosciences has divested Yusimry (adalimumab-aqvh), a biosimilar to AbbVie’s rheumatoid arthritis therapy Humira, to Hong Kong King-Friend Industrial (HKF) …
By effectively harnessing this globally unparalleled and extensive health dataset, we have an opportunity to attract and engage global life …
In our increasingly interconnected world, technology has woven itself seamlessly into the fabric of our daily lives. From the moment …
As healthcare demands continue to surge, innovation is an ever-pressing necessity. At the heart of this transformation lies a precious …
Hot on the heels of securing $259m in Series C financing three months ago, Alumis has raised a further $250m …
Biotechnology company Holoclara has secured an oversubscribed $16m in a Series A financing round, earmarked for the advancement of new …
Eisai and Biogen have announced the introduction of LEQEMBI (lecanemab) for the treatment of Alzheimer's disease (AD) in China. The treatment …
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for Pfizer and …
AbbVie has acquired biotechnology company Celsius Therapeutics in a deal valued at $250m in cash. Celsius focuses on developing new …
While the playground for drug discovery and development has changed, the name of the game for pharma and biotechs remains …
US-based 2seventy bio has completed an asset purchase agreement (APA) to divest its haemophilia A candidate to Novo Nordisk. 2seventy bio …
The US Food and Drug Administration (FDA) has approved Verona Pharma’s Ohtuvayre (ensifentrine) as a maintenance treatment for chronic obstructive …